Protein Predicts Skeletal Events in Prostate Cancer
Bone-specific alkaline phosphatase associated with earlier fractures and radiotherapy
TUESDAY, Sept. 18 (HealthDay News) -- Men with metastatic prostate cancer are at greater risk of skeletal complications when they have elevated levels of serum bone-specific alkaline phosphatase (BAP), researchers report in the August issue of Urology.
Matthew R. Smith, M.D., of the Massachusetts General Hospital in Boston, and colleagues extracted data collected from an earlier trial on 643 men with hormone-refractory prostate cancer with bone metastases. The primary outcome was time to first skeletal-related event.
Various univariate and multivariate analyses showed associations between shorter time to first skeletal-related event and levels of lactate dehydrogenase, prostate-specific antigen and urinary N-telopeptide as well as BAP. However, BAP was the only baseline variable consistently associated with the risk of adverse skeletal outcomes in each of the analyses, including time to first pathological fracture and time to radiotherapy to bone.
The authors conclude that their findings "could help inform the design of future clinical trials of bone-targeted therapy in men with prostate cancer."